Cardiovascular Drug Highlight: Hirudin

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Hirudin is a polypeptide of 65 to 66 amino acids derived from the saliva of the medicinal leech Hirudo medicinalis. It is the most potent naturally occurring specific inhibitor of thrombin. Through genetic engineering, recombinant forms of hirudin (r-hirudin) have been made available in sufficient quantities for therapeutic use. Because hirudin is capable of inhibiting clot-bound thrombin and fluid-phase thrombin, it has great potential for management of patients with various types of thromboembolic complications. Clinical trials with hirudin have been conducted in patients with coronary artery disease, heparin-induced thrombocytopenia, and in patients undergoing orthopedic surgery. The results of selected clinical trials in each of these areas are reviewed here. At present, most clinical benefits of r-hirudin have been demonstrated in the management of patients with heparin-induced thrombocytopenia. For this reason, lepirudin (a form of r-hirudin) has recently been approved by the United States Food and Drug Administration (FDA) for anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease.

Original languageEnglish (US)
Pages (from-to)41-49
Number of pages9
JournalHeart Disease
Volume1
Issue number1
StatePublished - Mar 1999

Fingerprint

Hirudins
Cardiovascular Agents
Thrombin
Thrombocytopenia
Heparin
Hirudo medicinalis
Clinical Trials
Leeches
Genetic Engineering
Therapeutic Uses
United States Food and Drug Administration
Saliva
Orthopedics
Coronary Artery Disease
Amino Acids
Peptides

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cardiovascular Drug Highlight : Hirudin. / Cheng-Lai, Angela.

In: Heart Disease, Vol. 1, No. 1, 03.1999, p. 41-49.

Research output: Contribution to journalArticle

@article{b903d7347e24478d907685de92dbb93d,
title = "Cardiovascular Drug Highlight: Hirudin",
abstract = "Hirudin is a polypeptide of 65 to 66 amino acids derived from the saliva of the medicinal leech Hirudo medicinalis. It is the most potent naturally occurring specific inhibitor of thrombin. Through genetic engineering, recombinant forms of hirudin (r-hirudin) have been made available in sufficient quantities for therapeutic use. Because hirudin is capable of inhibiting clot-bound thrombin and fluid-phase thrombin, it has great potential for management of patients with various types of thromboembolic complications. Clinical trials with hirudin have been conducted in patients with coronary artery disease, heparin-induced thrombocytopenia, and in patients undergoing orthopedic surgery. The results of selected clinical trials in each of these areas are reviewed here. At present, most clinical benefits of r-hirudin have been demonstrated in the management of patients with heparin-induced thrombocytopenia. For this reason, lepirudin (a form of r-hirudin) has recently been approved by the United States Food and Drug Administration (FDA) for anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease.",
author = "Angela Cheng-Lai",
year = "1999",
month = "3",
language = "English (US)",
volume = "1",
pages = "41--49",
journal = "Heart Disease",
issn = "1521-737X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Cardiovascular Drug Highlight

T2 - Hirudin

AU - Cheng-Lai, Angela

PY - 1999/3

Y1 - 1999/3

N2 - Hirudin is a polypeptide of 65 to 66 amino acids derived from the saliva of the medicinal leech Hirudo medicinalis. It is the most potent naturally occurring specific inhibitor of thrombin. Through genetic engineering, recombinant forms of hirudin (r-hirudin) have been made available in sufficient quantities for therapeutic use. Because hirudin is capable of inhibiting clot-bound thrombin and fluid-phase thrombin, it has great potential for management of patients with various types of thromboembolic complications. Clinical trials with hirudin have been conducted in patients with coronary artery disease, heparin-induced thrombocytopenia, and in patients undergoing orthopedic surgery. The results of selected clinical trials in each of these areas are reviewed here. At present, most clinical benefits of r-hirudin have been demonstrated in the management of patients with heparin-induced thrombocytopenia. For this reason, lepirudin (a form of r-hirudin) has recently been approved by the United States Food and Drug Administration (FDA) for anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease.

AB - Hirudin is a polypeptide of 65 to 66 amino acids derived from the saliva of the medicinal leech Hirudo medicinalis. It is the most potent naturally occurring specific inhibitor of thrombin. Through genetic engineering, recombinant forms of hirudin (r-hirudin) have been made available in sufficient quantities for therapeutic use. Because hirudin is capable of inhibiting clot-bound thrombin and fluid-phase thrombin, it has great potential for management of patients with various types of thromboembolic complications. Clinical trials with hirudin have been conducted in patients with coronary artery disease, heparin-induced thrombocytopenia, and in patients undergoing orthopedic surgery. The results of selected clinical trials in each of these areas are reviewed here. At present, most clinical benefits of r-hirudin have been demonstrated in the management of patients with heparin-induced thrombocytopenia. For this reason, lepirudin (a form of r-hirudin) has recently been approved by the United States Food and Drug Administration (FDA) for anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease.

UR - http://www.scopus.com/inward/record.url?scp=0033086427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033086427&partnerID=8YFLogxK

M3 - Article

C2 - 11720603

AN - SCOPUS:0033086427

VL - 1

SP - 41

EP - 49

JO - Heart Disease

JF - Heart Disease

SN - 1521-737X

IS - 1

ER -